Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 251 - 275 of 14501 in total

Ferric derisomaltose

Iron deficiency is an extremely common condition and is the most frequent cause of anemia worldwide. Iron deficiency results when iron intake, iron stores, and loss of iron from the body do not adequately support production of erythrocytes, also known as red blood cells. Though it is generally considered non...
Approved
Matched Description: … This drug is a complex of iron (III) hydroxide and derisomaltose. ... Iron deficiency is an extremely common condition and is the most frequent cause of anemia worldwide. ... Iron deficiency results when iron intake, iron stores, and loss of iron from the body do not adequately …

Potassium bicarbonate

Potassium bicarbonate is a white, crystalline, slightly alkaline and salty substance. It is produced by the passage of carbon dioxide through an aqueous potassium carbonate solution. It is used in medicine as an antacid. It is registered in the FDA under the section of suitable, safe and effective ingredients for...
Approved
Matched Description: … Potassium bicarbonate is a white, crystalline, slightly alkaline and salty substance. ... [T141] It is registered in the FDA under the section of suitable, safe and effective ingredients for …
Matched Mixtures name: … Coenzyme Q10 Isotonix Vitamin and Mineral Supplement ... Isotonix Advanced B-complex Vitamins With Potassium and Magnesium …
Matched Categories: … Alimentary Tract and Metabolism …

Deflazacort

Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dystrophin gene, which...
Approved
Investigational
Matched Description: … This disease can cause serious muscle weakness and progressive breathing and cardiovascular disability ... , severely impacting patient quality of life and survival. ... It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA. …
Matched Categories: … Sex Hormones and Insulins …

Taliglucerase alfa

Taliglucerase alfa is the recombinant active form of the human lysosomal enzyme, β-glucocerebrosidase. It was approved in 2012 and is marketed under the name Elelyso for use in patients with type 1 Gaucher's disease.
Approved
Investigational
Matched Description: … It was approved in 2012 and is marketed under the name Elelyso for use in patients with type 1 Gaucher's …
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism …

Olsalazine

Olsalazine is an aminosalicylate and a prodrug of mesalamine (5-aminosalicylic acid, 5-ASA). It was first developed for delivering mesalamine to the colon without the use of sulfapyridine. Olsalazine comprises two mesalamine molecules joined by an azo bridge, which is cleaved in the colon. Olsalazine is an anti-inflammatory agent that works...
Approved
Matched Description: … Olsalazine is an aminosalicylate and a prodrug of [mesalamine] (5-aminosalicylic acid, 5-ASA). ... , subsequently reducing the production of pro-inflammatory factors like prostaglandin and leukotriene ... [A257078] Olsalazine is an anti-inflammatory agent that works by inhibiting cyclooxygenase and lipoxygenase …
Matched Categories: … Alimentary Tract and Metabolism …

Human thrombin

Human thrombin is a sterile solution, pH 6.8-7.2, containing highly purified human thrombin for the activation of clotting. Thrombin is a highly specific serine protease encoded by the F2 gene that transforms soluble fibrinogen into insoluble fibrin. This transformation mimics the final coagulation cascade step which involves the clotting mass...
Approved
Matched Description: … achieves hemostasis and sealing of open tissues. ... the final coagulation cascade step which involves the clotting mass that adheres to the wound surface and …

Zafirlukast

Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), which is usually taken just once...
Approved
Investigational
Matched Description: … /or long-acting bronchodilator. ... It is available as a tablet and is usually dosed twice daily. ... on the CysLT1 receptors, thus reducing constriction of the airways, build-up of mucus in the lungs and …
Matched Categories: … Hormones, Hormone Substitutes, and Hormone Antagonists …

Medroxyprogesterone acetate

Medroxyprogesterone acetate (MPA) is a progesterone derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prevent pregnancy, manage pain in endometriosis, prevent pregnancy, and is also...
Approved
Investigational
Matched Description: … in palliative care for endometrial and renal carcinoma. ... vaginal atrophy, prevent pregnancy, manage pain in endometriosis, prevent pregnancy, and is also used ... endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and …
Matched Categories: … Hormones and Related Agents ... Progesterone and Derivatives ... medroxyprogesterone and estrogen ... medroxyprogesterone and estrogen ... medroxyprogesterone and estradiol …

Beremagene geperpavec

Beremagene geperpavec is a live, replication-defective herpes simplex virus type 1 (HSV-1)-based vector therapy. Developed by Krystal Biotech, it was first approved by the FDA on May 19, 2023, for the treatment of wounds associated with dystrophic epidermolysis bullosa (DEB). DEB is caused by mutations in the COL7A1 gene that...
Approved
Matched Categories: … Cellular and Gene Therapy ... Preparations for Treatment of Wounds and Ulcers …

Tecovirimat

The World Health Organization declared smallpox, a contagious and sometimes fatal infectious disease, eradicated in 1980. However, there have been longstanding concerns that smallpox may be used as a bioweapon.[A35133,L3614] Tecovirimat is an antiviral drug that was identified via a high-throughput screen in 2002. It is effective against all orthopoxviruses,...
Approved
Investigational
Matched Description: … to treat monkeypox and cowpox in adults and children. ... [L40154] Tecovirimat is available as both oral and intravenous formulations.[L41835] ... The World Health Organization declared smallpox, a contagious and sometimes fatal infectious disease, …

Cimetidine

A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant therapy.
Approved
Investigational
Matched Description: … It inhibits gastric acid secretion, as well as pepsin and gastrins output. …
Matched Categories: … Alimentary Tract and Metabolism ... Metabolic Side Effects of Drugs and Substances ... Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord) …
Matched Products: … Up and Up Acid Reducer …

Agalsidase beta

Agalsidase beta is a recombinant human α-galactosidase A similar to agalsidase alfa. While patients generally do not experience a clinically significant difference in outcomes between the two drugs, some patients may experience greater benefit with agalsidase beta.[A220228,A220233] Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa,...
Approved
Investigational
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins …

Agalsidase alfa

Agalsidase alfa is a recombinant human α-galactosidase A similar to agalsidase beta. While patients generally do not experience a clinically significant difference in outcomes between the two drugs, some patients may experience greater benefit with agalsidase beta.[A220228,A220233] Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa,...
Approved
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins …

Ethambutol

Ethambutol is a bacteriostatic agent indicated alongside medications such as isoniazid, rifampin, and pyrazinamide in the treatment of pulmonary tuberculosis. Ethambutol was first described in the literature in 1961. It was developed out of a need for therapies active against isoniazid resistant strains of Mycobacterium tuberculosis. Ethambutol was granted FDA...
Approved
Matched Description: … Ethambutol is a bacteriostatic agent indicated alongside medications such as [isoniazid], [rifampin], and …
Matched Categories: … ethambutol and isoniazid ... rifampicin, ethambutol and isoniazid ... rifampicin, pyrazinamide, ethambutol and isoniazid …

Cabotegravir

Cabotegravir, or GSK1265744, is an HIV-1 integrase inhibitor that is prescribed with the non-nucleoside reverse transcriptase inhibitor, rilpivirine.[A227668,L31188,L31193] Early research into cabotegravir showed it had lower oral bioavailability than dolutegravir, which resulted in the development of long acting monthly intramuscular injection formulation for cabotegravir.[A227668,L31193] Cabotegravir was granted FDA approval on...
Approved
Investigational
Matched Description: … it had lower oral bioavailability than [dolutegravir],[A227668] which resulted in the development of long ... combination product was granted FDA approval for dosing every two months on February 01, 2022 [L40084] and …

Sparsentan

Sparsentan is a dual antagonist of the endothelin type A receptor (ETAR) and the angiotensin II (Ang II) type 1 receptor (AT1R) with a similar affinity for both (9.3 nM for ETAR and 0.8 nM for AT1R).[A257330,L45300] Sparsentan is first in its class and orally active, and was created by...
Approved
Investigational
Matched Description: … [A257330,L45300] Sparsentan is first in its class and orally active, and was created by merging the structural ... Sparsentan is a dual antagonist of the endothelin type A receptor (ETAR) and the angiotensin ... [L45315] The use of sparsentan may cause hepatotoxicity and embryo-fetal toxicity.[L45300] …

Tetradecyl hydrogen sulfate (ester)

Sodium tetradecyl sulfate is an anionic surface-active agent which is used for its wetting properties in the industry and is also used in medicine as a blood vessel irritant and sclerosing agent for hemorrhoids and varicose veins . Sodium tetradecyl sulfate has been widely used since the 1950s, and in...
Approved
Matched Description: … Also noted was an unspecified number of episodes of epidermal necrosis without significant long-term ... is also used in medicine as a blood vessel irritant and sclerosing agent for hemorrhoids and varicose ... sulfate is an anionic surface-active agent which is used for its wetting properties in the industry and …

Pindolol

Pindolol is a first generation non-selective beta blocker used in the treatment of hypertension. Early research into the use of pindolol found it had chronotropic effects, and so further investigation focused on the treatment of arrhythmia. Research into pindolol's use in the treatment of hypertension began in the early 1970s....
Approved
Investigational
Matched Description: … [L32353] Early research into the use of pindolol found it had chronotropic effects, and so further investigation …
Matched Categories: … pindolol and other diuretics …

Avapritinib

Avapritinib, or BLU-285, is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and advanced systemic mastocytosis.[A189339,L40363] It is one of the first medications available for the treatment of multidrug resistant cancers. Avapritinib shares a...
Approved
Investigational
Matched Description: … Avapritinib, or BLU-285,[A189327] is a selective tyrosine kinase inhibitor of KIT and platelet derived ... receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and ... Avapritinib was granted FDA approval on 9 January 2020 [L40363] and EMA approval on 24 September 2020 …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Emtricitabine

Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) indicated for the treatment of HIV infection in adults or combined with tenofovir alafenamide for the prevention of HIV-1 infection in high risk adolescents and adults. Emtricitabine is a cytidine analogue. The drug works by inhibiting HIV reverse transcriptase, preventing transcription of...
Approved
Investigational
Matched Description: … combined with [tenofovir alafenamide] for the prevention of HIV-1 infection in high risk adolescents and …
Matched Mixtures name: … Emtricitabine and Tenofovir Disoproxil Fumarate ... Emtricitabine and Tenofovir Disoproxil Fumarate ... Emtricitabine and Tenofovir Disoproxil Fumarate …
Matched Categories: … tenofovir disoproxil and emtricitabine ... emtricitabine and tenofovir alafenamide ... Nucleic Acids, Nucleotides, and Nucleosides ... emtricitabine, tenofovir disoproxil and efavirenz ... emtricitabine, tenofovir disoproxil and rilpivirine …

Nirsevimab

Nirsevimab (MEDI8897) is a recombinant human immunoglobulin G1 kappa (IgG1ĸ) monoclonal antibody used to prevent respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants. It binds to the prefusion conformation of the RSV F protein, a glycoprotein involved in the membrane fusion step of the viral entry...
Approved
Investigational
Matched Description: … neutralizes several RSV A and B strains. ... antibody used to prevent respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and ... the RSV F protein, a glycoprotein involved in the membrane fusion step of the viral entry process, and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Immune Sera and Immunoglobulins …

Vildagliptin

Vildagliptin (LAF237) is an orally active antihyperglycemic agent that selectively inhibits the dipeptidyl peptidase-4 (DPP-4) enzyme. It is used to manage type II diabetes mellitus, where GLP-1 secretion and insulinotropic effects are impaired. By inhibiting DPP-4, vildagliptin prevents the degradation of glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP),...
Approved
Investigational
Matched Description: … Elevated levels of GLP-1 and GIP consequently results in improved glycemic control. ... It is used to manage type II diabetes mellitus, where GLP-1 secretion and insulinotropic effects are ... A232488] By inhibiting DPP-4, vildagliptin prevents the degradation of glucagon-like peptide 1 (GLP-1) and …
Matched Categories: … Alimentary Tract and Metabolism ... metformin and vildagliptin …

Eculizumab

Eculizumab is a monoclonal antibody that targets complement protein C5.[L6919,A2245] Binding to this protein prevents the activation of a complement terminal complex, which is used to treat a number of autoimmune conditions.[L6919,A2245,A2246] Eculizumab was granted FDA approval on 16 March 2007. In Q1 2023, the EMA's Committee for Medicinal Products...
Approved
Investigational
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Melphalan flufenamide

Melphalan flufenamide, also known as melflufen or J1, is a prodrug of melphalan.[A230123,L32173] Melphalan flufenamide is more readily uptaken by cells than melphalan, and is cleaved to the active metabolite by aminopeptidases. In vitro models show that melphalan is 10 to hundreds of times more potent than melphalan. The increased...
Approved
Withdrawn
Matched Description: … [A230123,L32173] Melphalan flufenamide is more readily uptaken by cells than melphalan, and is cleaved ... which showed a decrease in overall survival in comparison to standard treatment with [pomalidomide] and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Crizanlizumab

Crizanlizumab is a humanized IgG2 monoclonal antibody used to reduce the frequency of vaso-occlusive crises in patients with sickle cell disease. Sickle cell disease is a genetically inherited condition prevalent in the Middle East, Africa, and certain parts of India. The genetic mutation associated with this disease leads to the...
Approved
Investigational
Matched Description: … It was developed by Novartis and was granted FDA approval on November 15, 2019. ... L10097] Sickle cell disease is a genetically inherited condition prevalent in the Middle East, Africa, and ... Sickle cell disease can lead to excruciating pain, stroke, infection, and various other complications …
Matched Categories: … Blood and Blood Forming Organs ... Amino Acids, Peptides, and Proteins …
Displaying drugs 251 - 275 of 14501 in total